Using a patient’s own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.
The research team cautions that the work, done only in the laboratory, is years away from clinical use in patients, but should provide tools for developing gene therapies for SCD and a variety of other blood disorders.
In an article published online August 31 in
Image via Wikipedia
Researchers in the U.S. say they may have found a new and better source for harvesting stem cells: the placentas that are often discarded after birth.
The research from Children’s Hospital & Research Center Oakland found there are far more stem cells in placentas than in umbilical cord blood, the traditional source for stem cells, and they can be safely extracted for transplantation.
“Yes, the stem cells are there; yes, they are viable; and yes, we can get them out,” declared Dr. Frans Kuypers, one of the scientists who led the research with fellow scientist Vladimir Serikov.
The study was
Image via Wikipedia
Dozens of people who were blinded or otherwise suffered severe eye damage when they were splashed with caustic chemicals had their sight restored with transplants of their own stem cells — a stunning success for the burgeoning cell-therapy field, Italian researchers reported Wednesday.
The treatment worked completely in 82 of 107 eyes and partially in 14 others, with benefits lasting up to a decade so far. One man whose eyes were severely damaged more than 60 years ago now has near-normal vision.
“This is a roaring success,” said ophthalmologist Dr. Ivan Schwab of the University of California, Davis, who
Scientists and transplant clinicians at the Ansary Stem Cell Institute at Weill Cornell Medical College and the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center have been awarded a $15.7 million, four-year research grant from the New York State Stem Cell Science Program (NYSTEM).
The scientists will translate their approach to manipulate hematopoietic stem cells to cure acquired and inherited blood disorders. For many patients with such blood diseases, including sickle cell disease, the only hope for a cure requires transplanting normal blood stem cells.
But in many instances suitable blood stem cells cannot be found or there are
The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
The results of the StemEx study are expected during the second half of 2012
Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma,